These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
359 related articles for article (PubMed ID: 9865827)
21. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases. Roser F; Samii M; Ostertag H; Bellinzona M Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263 [TBL] [Abstract][Full Text] [Related]
22. Pathological analyses of early recurrence and malignant transformation in meningiomas. Arai H; Beppu T; Wada T; Yoshida Y; Kubo Y; Suzuki M; Ogawa A Brain Tumor Pathol; 1998; 15(1):37-40. PubMed ID: 9879462 [TBL] [Abstract][Full Text] [Related]
23. Significance of MIB-1 staining indices in meningiomas: comparison of two counting methods. Nakasu S; Li DH; Okabe H; Nakajima M; Matsuda M Am J Surg Pathol; 2001 Apr; 25(4):472-8. PubMed ID: 11257621 [TBL] [Abstract][Full Text] [Related]
24. Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature. Wolfsberger S; Doostkam S; Boecher-Schwarz HG; Roessler K; van Trotsenburg M; Hainfellner JA; Knosp E Neurosurg Rev; 2004 Oct; 27(4):238-45. PubMed ID: 15168138 [TBL] [Abstract][Full Text] [Related]
25. Cyclin D1 and MIB-1 immunohistochemistry in pilocytic astrocytomas: a study of 48 cases. Machen SK; Prayson RA Hum Pathol; 1998 Dec; 29(12):1511-6. PubMed ID: 9865840 [TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry. Prayson RA Ann Diagn Pathol; 1999 Feb; 3(1):11-8. PubMed ID: 9990108 [TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas. Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125 [TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas. Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227 [TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas. Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133 [TBL] [Abstract][Full Text] [Related]
30. Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas. Ohkoudo M; Sawa H; Hara M; Saruta K; Aiso T; Ohki R; Yamamoto H; Maemura E; Shiina Y; Fujii M; Saito I J Neurooncol; 1998 May; 38(1):41-9. PubMed ID: 9540056 [TBL] [Abstract][Full Text] [Related]
32. Proliferation and progesterone receptor status in benign meningiomas are not age dependent. Roser F; Nakamura M; Ritz R; Bellinzona M; Dietz K; Samii M; Tatagiba MS Cancer; 2005 Aug; 104(3):598-601. PubMed ID: 15952201 [TBL] [Abstract][Full Text] [Related]
33. Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas. Langford LA; Cooksley CS; DeMonte F Hum Pathol; 1996 Apr; 27(4):350-4. PubMed ID: 8617477 [TBL] [Abstract][Full Text] [Related]
34. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II. Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806 [TBL] [Abstract][Full Text] [Related]
35. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases. Korshunov A; Shishkina L; Golanov A Arch Pathol Lab Med; 2002 Sep; 126(9):1079-86. PubMed ID: 12204057 [TBL] [Abstract][Full Text] [Related]
36. Mitosin, a novel marker of cell proliferation and early recurrence in intracranial meningiomas. Konstantinidou AE; Korkolopoulou P; Kavantzas N; Mahera H; Thymara I; Kotsiakis X; Perdiki M; Patsouris E; Davaris P Histol Histopathol; 2003 Jan; 18(1):67-74. PubMed ID: 12507285 [TBL] [Abstract][Full Text] [Related]
37. [Analysis of the proliferative potential of meningiomas with MIB-1 monoclonal antibodies]. Miyagami M; Shibuya T; Miyagi A; Tsubokawa T No To Shinkei; 1996 Jan; 48(1):39-43. PubMed ID: 8679317 [TBL] [Abstract][Full Text] [Related]
38. Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas. Antinheimo J; Haapasalo H; Haltia M; Tatagiba M; Thomas S; Brandis A; Sainio M; Carpen O; Samii M; Jääskeläinen J J Neurosurg; 1997 Oct; 87(4):610-4. PubMed ID: 9322850 [TBL] [Abstract][Full Text] [Related]
39. [Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study]. Wang CL; Mei JH; Wang SS; Xu S; Xu LL; Xiong YF Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):156-60. PubMed ID: 20450760 [TBL] [Abstract][Full Text] [Related]
40. Prognostic Value of Ki-67 Labeling Index and Postoperative Radiotherapy in WHO Grade II Meningioma. Choi Y; Lim DH; Yu JI; Jo K; Nam DH; Seol HJ; Lee JI; Kong DS; Suh YL; Nam H Am J Clin Oncol; 2018 Jan; 41(1):18-23. PubMed ID: 26270441 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]